乳腺癌耐药蛋白在肿瘤中的研究进展  

Research Progress of Breast Cancer Resistance Protein in Tumor

作　　者：吴娜 刘安立 余国行 

机构地区：[1]解放军第四六四医院综合内科,天津300381

出　　处：《医学综述》2018年第2期295-300,共6页Medical Recapitulate

摘　　要：肿瘤细胞的多药耐药性(MDR)是导致临床肿瘤治疗失败的主要原因之一,而其发生主要与多药耐药基因的高表达有关。目前,公认的与MDR关系最为密切的耐药蛋白有3个,即P糖蛋白、乳腺癌耐药蛋白(BCRP)和多药耐药相关蛋白1,分别由腺苷三磷酸(ATP)结合盒B亚家族成员1/MDR1、ATP结合盒亚家族G成员2和ATP结合盒亚家族C成员1基因编码。除促进肿瘤细胞化疗耐药外,上述3种耐药蛋白还能促进靶向治疗和内分泌治疗耐药,甚至还参与细胞内信号转导和基因的表达调控,因此肿瘤组织中多药耐药蛋白的高表达成为患者预后不良的标志之一。未来,需深入研究BCRP的功能以为逆转肿瘤耐药和寻找新的抗肿瘤治疗策略提供依据。The multidrug resistance( MDR) of tumor cells is one of the major causes of failure of clinical tumor therapy,and its occurrence is mainly related to the high expression of multidrug resistance genes. At present,there are three recognized drug resistance proteins that are most closely related to MDR,i. e. P-glycoprotein,breast cancer resistance protein( BCRP) and multidrug resistance associated protein 1,respectively encoded by adenosine triphosphate( ATP)binding cassette subfamily B member 1/MDR1,ATP-binding cassette subfamily G member 2 and ATP-binding cassette subfamily C member 1 gene. In addition to promoting chemotherapeutic drug resistance of tumor cells,the three kinds of resistance protein can also promote targeted therapy and endocrine therapy resistance,and is also involved in signal transduction and gene expression regulation in cells,so the high expression tumor multidrug resistance protein has become one of the signs of poor prognosis. In the future,it is necessary to study the function of BCRP in order to provide a basis for reversing tumor drug resistance and finding new antitumor treatment strategies.

关 键 词：乳腺癌耐药蛋白 肿瘤 多药耐药性 P糖蛋白 

分 类 号：R737.9[医药卫生—肿瘤]